ZA961018B - Oral dosage-forms containing a beta-lactam antibiotic. - Google Patents

Oral dosage-forms containing a beta-lactam antibiotic.

Info

Publication number
ZA961018B
ZA961018B ZA9601018A ZA961018A ZA961018B ZA 961018 B ZA961018 B ZA 961018B ZA 9601018 A ZA9601018 A ZA 9601018A ZA 961018 A ZA961018 A ZA 961018A ZA 961018 B ZA961018 B ZA 961018B
Authority
ZA
South Africa
Prior art keywords
pct
beta
lactam antibiotic
granulate
oral dosage
Prior art date
Application number
ZA9601018A
Other languages
English (en)
Inventor
Gerrit Jan Sijbrands
Robertus Cornelis Van Koutrik
Original Assignee
Yamanouchi Europ Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Europ Bv filed Critical Yamanouchi Europ Bv
Publication of ZA961018B publication Critical patent/ZA961018B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
ZA9601018A 1995-02-08 1996-02-08 Oral dosage-forms containing a beta-lactam antibiotic. ZA961018B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95200313 1995-02-08

Publications (1)

Publication Number Publication Date
ZA961018B true ZA961018B (en) 1997-08-08

Family

ID=8220003

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9601018A ZA961018B (en) 1995-02-08 1996-02-08 Oral dosage-forms containing a beta-lactam antibiotic.

Country Status (19)

Country Link
US (1) US5948422A (fr)
EP (1) EP0801559B1 (fr)
CN (1) CN1125636C (fr)
AT (1) ATE216576T1 (fr)
AU (1) AU4789696A (fr)
BG (1) BG63528B1 (fr)
BR (1) BR9607189A (fr)
CZ (1) CZ293718B6 (fr)
DE (1) DE69620866T2 (fr)
DK (1) DK0801559T3 (fr)
EA (2) EA000361B1 (fr)
ES (1) ES2175073T3 (fr)
HU (1) HU227938B1 (fr)
MX (1) MX9706062A (fr)
NO (1) NO319993B1 (fr)
PL (1) PL186386B1 (fr)
PT (1) PT801559E (fr)
WO (1) WO1996024337A1 (fr)
ZA (1) ZA961018B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
US6242006B1 (en) * 1996-07-16 2001-06-05 Gist-Brocades B.V. β-lactam granules free of organic solvents
US6080427A (en) * 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
JP2002505269A (ja) * 1998-03-06 2002-02-19 エウランド インターナショナル ソシエタ ペル アチオニ 急速崩壊錠剤
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
DE19922537A1 (de) * 1999-05-10 2000-11-16 Roland Bodmeier Darreichungsform zur Applikation in Körperöffnungen
AU2001288102A1 (en) * 2000-09-22 2002-04-02 Takeda Chemical Industries Ltd. Solid preparations
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
BR0206979A (pt) * 2001-02-05 2004-04-20 Scherer Technologies Inc R P Métodos e composições para reduzir o paladar de agentes farmaceuticamente ativos
RU2190403C1 (ru) * 2001-09-27 2002-10-10 Нестерук Владимир Викторович Фармацевтическая композиция, обладающая антибактериальным действием, и способ ее получения
WO2003077842A2 (fr) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company Suspension orale de gout agreable et procede associe
AU2003235962A1 (en) * 2002-10-02 2004-04-23 Meiji Seika Kaisha, Ltd. Antibacterial medicinal composition of enhanced oral absorptivity
PT1578422E (pt) * 2002-12-20 2007-06-14 Niconovum Ab Material particulado contendo nicotina fisicamente e quimicamente estável
CA2531022C (fr) * 2003-07-03 2014-09-09 Jannette Dufour Compositions contenant des cellules de sertoli et des cellules myoides et leurs utilisations dans des greffes cellulaires
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
AU2006318815B2 (en) * 2005-11-17 2010-08-19 Novartis Ag Pharmaceutical composition
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
JP2010500871A (ja) * 2006-07-28 2010-01-14 セルトセル・バイオテクノロジー・（ユーエス）・コーポレイション 成熟セルトリ細胞およびその使用
CA2736531C (fr) * 2008-09-17 2016-10-25 Modoral Brands Inc. Procede de preparation d'une composition de tabac a priser
CA2746768A1 (fr) * 2008-12-17 2010-07-08 Altheus Therapeutics, Inc. Formules pour lavement
WO2023204773A1 (fr) * 2022-04-20 2023-10-26 Bilim Ilac Sanayii Ve Ticaret A.S. Formulations de comprimés pour le traitement d'infections de l'appareil urinaire et procédé de préparation de telles formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3344030A (en) * 1964-06-15 1967-09-26 American Home Prod Reinforced directly compressed nongranulated pharmaceutical crystalline lactose tables
DE2251250C3 (de) * 1972-10-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung hochdosierter Antibiotica-Tabletten
DE2251249A1 (de) * 1972-10-19 1974-05-02 Hoechst Ag Verfahren zur herstellung von penicillin-verbindungen enthaltenden tabletten
DE3887179T2 (de) * 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
US5049394A (en) * 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
EP0330284B1 (fr) * 1988-02-25 1994-07-27 Yamanouchi Europe B.V. Procédé de préparation d'un granulé pharmaceutique
US5643591A (en) * 1991-01-16 1997-07-01 Fmc Corporation Solid dosage forms
DK0755258T3 (da) * 1994-04-13 2002-05-13 Res Corp Technologies Inc Fremgangsmåde til behandling af sygdom ved at anvende Sertoli-celler og allo-transplantater eller xeno-transplantater
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin

Also Published As

Publication number Publication date
AU4789696A (en) 1996-08-27
EP0801559A1 (fr) 1997-10-22
CN1125636C (zh) 2003-10-29
MX9706062A (es) 1997-10-31
PT801559E (pt) 2002-09-30
NO973646L (no) 1997-09-11
EA199700093A1 (ru) 1998-02-26
US5948422A (en) 1999-09-07
BR9607189A (pt) 1997-11-11
EA199900205A1 (ru) 2000-06-26
DE69620866D1 (de) 2002-05-29
EA003736B1 (ru) 2003-08-28
BG101822A (en) 1998-04-30
WO1996024337A1 (fr) 1996-08-15
CZ230297A3 (en) 1997-11-12
ATE216576T1 (de) 2002-05-15
EA000361B1 (ru) 1999-06-24
CN1173816A (zh) 1998-02-18
DK0801559T3 (da) 2002-06-17
HUP9801677A2 (hu) 1998-11-30
PL186386B1 (pl) 2004-01-30
HU227938B1 (en) 2012-06-28
BG63528B1 (bg) 2002-04-30
NO973646D0 (no) 1997-08-07
DE69620866T2 (de) 2003-02-27
PL321567A1 (en) 1997-12-08
EP0801559B1 (fr) 2002-04-24
CZ293718B6 (cs) 2004-07-14
NO319993B1 (no) 2005-10-10
HUP9801677A3 (en) 1999-05-28
ES2175073T3 (es) 2002-11-16

Similar Documents

Publication Publication Date Title
ZA961018B (en) Oral dosage-forms containing a beta-lactam antibiotic.
IL115309A0 (en) Pharmaceutical preparation containing metformin and processes for the production thereof
TW263499B (fr)
JO1969B1 (en) Granulation process for the preparation of rapidly dissolving and dissolving compounds containing a high amount of the drug
ZA965237B (en) A composition and a process for the preparation thereof
GB9821387D0 (en) Hydrocolloid confectionery
GB9517883D0 (en) Improved pharmaceutical ion exchange resin composition
IL115920A0 (en) 2,2-dichloroalkanecarboxylic acids process of their production and pharmaceutical agents containing these
MXPA00012199A (es) Composicion de goma de gelano modificada, proceso para la preparacion de la misma y uso de esta.
HU9700903D0 (en) Sulfonamide-substituted chromanes, process for producing them, their use as pharmaceutical compositions or diagnostica, and pharmaceutical compositions containing them
HUP9601358A3 (en) Fluoro-phenyl-substituted alkenyl-carboxylic-guanidines, process for producing them, their use as medicines or diagnostica, and pharmaceutical compositions containing them
ZA966163B (en) Novel galanthamine derivatives, process for the preparation thereof, their application as medical drugs, and pharmaceutical compositions containing said derivatives.
HU9601321D0 (en) Substituted (benzyloxy)-carbonyl-guanidine derivatives, process for producing them, their use as pharmaceutical compositions or diagnostica, and pharmaceutical compositions containing them
BR9909637A (pt) Processo para a produção de um tablete de uma composição particulada compactada, tablete de composição particulada compactada, e, usos de cristais ou acetato de sódio hidratado ou anidro, acetato de potássio ou misturas dos mesmos e de cristais ou triidrato de acetato de sódio hidratado ou anidro, acetato de potássio ou mistura dos mesmos
HUP9802492A3 (en) Benzisoxazole and indazole derivatives as antipsychotic agents, process for their preparation and pharmaceutical compositions containing the same
HU9501925D0 (en) Ortho-amine-substituted benzoyl-guanidine derivatives, process for producing them their pharmaceutical or diagnostical use, and pharmaceutical compositions containing them
HUP9602640A2 (en) Substituted benzoyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them and the use of the compds.
HUP0004663A3 (en) Substituted isoquinoline derivatives, process for producing them and use of them for producing pharmaceutical compositions as anticonvulsants and pharmaceutical compositions containing them
HUP0103347A3 (en) Aminoalcohol derivatives and their use as betha 3 adrenergic agonists, process for their preparation and pharmaceutical compositions containing them
IL130347A0 (en) Process for reducing sulfur and vat dyes
HUP9900263A3 (en) 11-acetyl-12,13-dioxabicyclo[8.2.1.]tridecenon derivatives, process for producing them and pharmaceutical compositions containing them
HUT50633A (en) Process for producing pharmaceutical compositions comprising 1,4-dihydropyridine derivatives
TW334424B (en) L-arginine aldehyde derivatives process for preparing them and pharmaceutical composition
IL117734A (en) Anellated beta-carbolines their preparation and pharmaceutical compositions containing them
HUT66204A (en) Phytoactive compositions containing n-phosphonomethyl-clycine monoammonium salts as active ingredients and process for producing the compositions and the active ingredients